Watch the MOA video to find out how MacroBID® does not contribute towards
rising antibiotic resistance in lower urinary tract infections

Click here for MOA video PI & references

MacroBID® 100 mg prolonged-release capsules
is licensed to be taken twice daily for 7 days for acute
or recurrent uncomplicated UTI and pyelitis5

  • Clinical cure rates range from 79-92% for a 5- to 7-day course of nitrofurantoin for lower UTI8,9
  • MacroBID® is generally well tolerated, with mild, reversible and predominantly gastrointestinal side effects5,8
  • NICE11 recommend MacroBID® as a first-line option for uncomplicated lower UTI if eGFR ≥45 ml/min*, in non-pregnant women† and men aged ≥16 years, pregnant women† aged ≥12 years, and young people aged 12-155

*Nitrofurantoin is contraindicated in patients with renal dysfunction and in patients with an eGFR of less than 45 ml/min. Nitrofurantoin may be used with caution as short-course therapy only for the treatment of uncomplicated lower UTI in individual cases with an eGFR between 30-44 ml/min to treat resistant pathogens, when the benefits are expected to outweigh the risks.5 GFR stages classified as: mild (60-89 ml/min/1.73m2); mild-moderate (45-59 ml/min/1.73m2); moderate-severe (30-44 ml/min/1.73m2); severe (15-29 ml/min/1.73m2) and kidney failure (<15 ml/min/1.73m2).10

Nitrofurantoin is contraindicated in infants under 3 months of age as well as pregnant patients at term (during labour and delivery) because of the theoretical possibility of haemolytic anaemia in the foetus or in the newborn infant due to immature erythrocyte enzyme systems.5

Resist the resistance with MacroBID® – your tool in the fight against resistance in lower UTIs

Email icon

To arrange a call with the MacroBID team contact:
Visit macrobid.co.uk for more information

Prescribing information and references
  1. McNulty C. (2019). Urinary tract infections: when is it appropriate to prescribe an antibiotic? Guidelines in Practice. [Viewed 04 February 2021]. Available from: https://www.guidelinesinpractice.co.uk/urology/urinary-tract-infections-when-is-it-appropriate-to-prescribe-an-antibiotic/454498.article
  2. Shanmugam D., et al., (2016). Molecular Characterisation of nfsA Gene in Nitrofurantoin Resistant Uropathogens. J Clin Diagn Res. 10(6):DC05-DC09.
  3. Gardiner BJ, et al. Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems. Australian Prescriber 2019;42(1):14-19.
  4. Blass BE. (2019). Nitrofurantoin: a surprisingly successful drug. In: Basic Principles of Druf Discovery and Development. [Viewed 1 May 2020]. Available from: https://www.sciencedirect.com/topics/chemistry/nitrofurantoin.
  5. MacroBID ® (nitrofurantoin 100 mg prolonged–release capsules) Summary of Product Characteristics. ADVANZ Pharma, 25 March 2019. [Viewed 25 March 2021]. Available from: https://www.medicines.org.uk/emc/product/429.
  6. Sekyere, J.O., (2018). Genomic insights into nitrofurantoin resistance mechanisms and epidemiology in clinical Enterobacteriaceae. Future Science OA. 4(5), FSO293.
  7. National Institute of Health and Care Excellence. (2018). Urinary tract infection (lower): antimicrobial prescribing (NG109). [Viewed 25 March 2021]. Available from: https://www.nice.org.uk/guidance/ng109.
  8. Huttner, A., et al., (2015). Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrobial Chemotherapy. 70(9), 2456–2464.
  9. Gupta, K., et al., (2011). International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clinical Infectious Diseases. 52(5), e103–e120.
  10. Levey, A.S., et al., (2011). The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney International. 80(1), 17–28.

Date of preparation: November 2021 ADV/MAB/PM/0315